Dermatology Times, July 2025 (Vol. 46. No. 07)

Learn more about the in-depth topics covered in the July 2025 print issue of Dermatology Times.

AI revolutionizes skin care by personalizing product recommendations, enhancing customer satisfaction, and transforming dermatologist-patient interactions for better outcomes.

Young dermatologists should learn essential financial planning strategies to secure their future, including saving early, securing insurance, and budgeting effectively.

Matthew Zirwas, MD, discusses the complexities of safety analysis in psoriasis clinical trials, advocating for exposure-adjusted incidence rates to enhance risk communication.

The 2025 Fall Clinical Dermatology Conference energized PAs and NPs with innovative strategies, addressing burnout, digital branding, and personalized medicine.

Experts share how this year's RAD Conference showcased cutting-edge advancements in atopic dermatitis to enhance patient care and treatment strategies.

Hershel Dobkin, MD, FAAD, shares his experiences and the surprising reasons behind clinic delays, from patient needs to unexpected moments.

Our July cover story explores effective treatments for hidradenitis suppurativa, including procedural interventions and advanced therapies that enhance patient quality of life.

Art transforms dermatology by fostering dialogue, enhancing patient connection, and challenging biases, as medical students explore creative expression in health care.

Aesthetic medicine embraces a holistic approach to skin quality, defining it through measurable categories that enhance personalized treatment strategies.

Discover how trifarotene, a novel retinoid, effectively addresses adult acne and its long-term effects, enhancing skin health and quality of life.

For pregnant women, formulations with niacinamide, vitamin E, hyaluronic acid, and peptides may help support barrier function and reduce pigmentation without compromising safety.

Melanoma survivors share their diagnoses and advocate for early detection, routine skin exams, and public education to save lives.

Exclusive Report: A comprehensive look at the latest FDA approvals and pipeline developments in dermatology from the first half of 2025.

Christopher Bunick, MD, PhD, highlights how dupilumab transforms atopic dermatitis treatment in children, improving health outcomes and quality of life beyond skin symptoms.

Explore the latest advancements in dermatology in our July issue, from innovative treatments to AI in skin care, shaping the future of skin health and research.

At a recent Dermatology Times Case-Based Roundtable event, Michael Gold, MD, explored innovative vitiligo treatment strategies through complex cases and emerging therapies.

Abrocitinib’s targeted inhibition of JAK1 offers effective control of AD, but may, in rare instances, lead to a shift in immune expression resulting in paradoxical psoriasis.

Data from the Level Up study shows that switching from dupilumab to upadacitinib enables more patients to achieve optimal targets of skin clearance and itch relief.